Reference(s)
Click here to return to the Reference Table

Cancer type: Bladder


HGF/SF expression

Reference Number: 1
Joseph, A. et al. Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst 87, 372-7. (1995).
PubMed link      E-mail link

Reference Number: 2
Li, B., Kanamaru, H., Noriki, S., Fukuda, M. & Okada, K. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int J Urol 5, 436-40. (1998).
PubMed link      E-mail link

Reference Number: 549
Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 6, 1393-402 (2007)
PubMed link      E-mail link

Reference Number: 592
Wang P, Nishitani MA, Tanimoto S, Kishimoto T, Fukumori T, Takahashi M, Kanayama HO. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology. 69, 780-4 (2007)
PubMed link      E-mail link

Reference Number: 806
Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. J Urol. 181, 1353-60 (2009)
PubMed link      E-mail link

Reference Number: 808
Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol. 40, 496-504 (2009)
PubMed link      E-mail link

Reference Number: 853
Bhuvaneswari R, Gan YY, Lucky SS, Chin WW, Ali SM, Soo KC, Olivo M. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol Cancer. 7, 56 (2008)
PubMed link      E-mail link

Reference Number: 1392
Hofner T1, Macher-Goeppinger S, Klein C, Rigo-Watermeier T, Eisen C, Pahernik S, Hohenfellner M, Trumpp A, Sprick MR. Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer. J Urol. 190, 2263-70 (2013)
PubMed link      E-mail link

Reference Number: 1511
Chiba S, Tsuchiya N, Horikawa Y, Narita S, Inoue T, Akihama S, Saito M, Numakura K, Tsuruta H, Huang M, Satoh S, Habuchi T. Functional mononucleotide repeat polymorphism in the promoter region of HGF is associated with risk and malignant aggressiveness of bladder cancer. Int J Oncol. 44, 678-84 (2014)
PubMed link      E-mail link

Reference Number: 1745
Grimm S, Jennek S, Singh R, Enkelmann A, Junker K, Rippaus N, Berndt A, Friedrich K. Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine-chemokine loop. Exp Cell Res. 335, 1-11 (2015)
PubMed link      E-mail link

Met expression

Reference Number: 3
Cheng, H. L. et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 20, 1544-50. (2002).
PubMed link      E-mail link

Reference Number: 455
Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 92, 1906-14 (2005)
PubMed link      E-mail link

Reference Number: 549
Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 6, 1393-402 (2007)
PubMed link      E-mail link

Reference Number: 591
Wu TF, Wu H, Wang YW, Chang TY, Chan SH, Lin YP, Liu HS, Chow NH. Prohibitin in the pathogenesis of transitional cell bladder cancer. Anticancer Res. 27, 895-900 (2007)
PubMed link      E-mail link

Reference Number: 592
Wang P, Nishitani MA, Tanimoto S, Kishimoto T, Fukumori T, Takahashi M, Kanayama HO. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology. 69, 780-4 (2007)
PubMed link      E-mail link

Reference Number: 593
Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse. J Biol Chem. 282, 8123-33 (2007)
PubMed link      E-mail link

Reference Number: 627
Compérat E, Roupret M, Chartier-Kastler E, Bitker MO, Richard F, Camparo P, Capron F, Cussenot O. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract. J Urol. 179, 868-72 (2008)
PubMed link      E-mail link

Reference Number: 806
Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. J Urol. 181, 1353-60 (2009)
PubMed link      E-mail link

Reference Number: 808
Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol. 40, 496-504 (2009)
PubMed link      E-mail link

Reference Number: 853
Bhuvaneswari R, Gan YY, Lucky SS, Chin WW, Ali SM, Soo KC, Olivo M. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol Cancer. 7, 56 (2008)
PubMed link      E-mail link

Reference Number: 854
Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc Natl Acad Sci U S A. 105, 1925-30 (2008)
PubMed link      E-mail link

Reference Number: 1122
Yeh CY, Shin SM, Yeh HH, Wu TJ, Shin JW, Chang TY, Raghavaraju G, Lee CT, Chiang JH, Tseng VS, Lee YC, Shen CH, Chow NH, Liu HS. Transcriptional activation of the Axl and PDGFR-a by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer. 11, 139 (2011)
PubMed link      E-mail link

Reference Number: 1392
Hofner T1, Macher-Goeppinger S, Klein C, Rigo-Watermeier T, Eisen C, Pahernik S, Hohenfellner M, Trumpp A, Sprick MR. Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer. J Urol. 190, 2263-70 (2013)
PubMed link      E-mail link

Reference Number: 1393
Majumdar S1, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, Hager MH, Park PJ, Bellmunt J, Matusik RJ, Rosenberg JE, Adam RM. Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia. 15, 749-60 (2013)
PubMed link      E-mail link

Reference Number: 1431
Xu X1, Chen H, Lin Y, Hu Z, Mao Y, Wu J, Xu X, Zhu Y, Li S, Zheng X, Xie L. MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells. 36, 62-8 (2013)
PubMed link      E-mail link

Reference Number: 1480
Kluth M, Reynolds K, Rink M, Chun F, Dahlem R, Fisch M, Höppner W, Wagner W, Doh O, Terracciano L, Simon R, Sauter G, Minner S. Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genet. 207, 147-52 (2014)
PubMed link      E-mail link

Reference Number: 1744
Chiyomaru T, Seki N, Inoguchi S, Ishihara T, Mataki H, Matsushita R, Goto Y, Nishikawa R, Tatarano S, Itesako T, Nakagawa M, Enokida H. Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. Int J Oncol. 46, 487-96 (2015)
PubMed link      E-mail link

Reference Number: 1746
Matsumoto R, Tsuda M, Wang L, Maishi N, Abe T, Kimura T, Tanino M, Nishihara H, Hida K, Ohba Y, Shinohara N, Nonomura K, Tanaka S. Adaptor protein CRK induces epithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF/c-Met feedback loop. Cancer Sci. 106, 709-17 (2015)
PubMed link      E-mail link

Reference Number: 1834
Kim YW, Yun SJ, Jeong P, Kim SK, Kim SY, Yan C, Seo SP, Lee SK, Kim J, Kim WJ The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. PLoS One. 10, e0134552 (2015)
PubMed link      E-mail link

Poor Prognosis

Reference Number: 3
Cheng, H. L. et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 20, 1544-50. (2002).
PubMed link      E-mail link

Reference Number: 455
Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 92, 1906-14 (2005)
PubMed link      E-mail link

Reference Number: 592
Wang P, Nishitani MA, Tanimoto S, Kishimoto T, Fukumori T, Takahashi M, Kanayama HO. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology. 69, 780-4 (2007)
PubMed link      E-mail link

Reference Number: 808
Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol. 40, 496-504 (2009)
PubMed link      E-mail link

Reference Number: 1834
Kim YW, Yun SJ, Jeong P, Kim SK, Kim SY, Yan C, Seo SP, Lee SK, Kim J, Kim WJ The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. PLoS One. 10, e0134552 (2015)
PubMed link      E-mail link

Mutation of Met

In vitro studies

Reference Number: 3
Cheng, H. L. et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 20, 1544-50. (2002).
PubMed link      E-mail link

Reference Number: 549
Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 6, 1393-402 (2007)
PubMed link      E-mail link

Reference Number: 807
Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD, Yang AS, Jones PA, Liang G. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 6, e1000917 (2010)
PubMed link      E-mail link

Reference Number: 1392
Hofner T1, Macher-Goeppinger S, Klein C, Rigo-Watermeier T, Eisen C, Pahernik S, Hohenfellner M, Trumpp A, Sprick MR. Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer. J Urol. 190, 2263-70 (2013)
PubMed link      E-mail link

Animal models

Reference Number: 4
Bellusci, S. et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 9, 1091-9 (1994).
PubMed link      E-mail link

Reference Number: 5
Inui, M. et al. Enhanced gene expression of transforming growth factor-alpha and c-met in rat urinary bladder cancer. Urol Res 24, 55-60 (1996).
PubMed link      E-mail link

Reference Number: 1771
Dang Q, Song W, Xu D, Ma Y, Li F, Zeng J, Zhu G, Wang X, Chang LS, He D, Li L. Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog. 54, 831-40 (2015)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 549
Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 6, 1393-402 (2007)
PubMed link      E-mail link

Reference Number: 715
Arena S, Pisacane A, Mazzone M, Comoglio PM, Bardelli A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci U S A. 104, 11412-7 (2007)
PubMed link      E-mail link

Reference Number: 853
Bhuvaneswari R, Gan YY, Lucky SS, Chin WW, Ali SM, Soo KC, Olivo M. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol Cancer. 7, 56 (2008)
PubMed link      E-mail link

Reference Number: 1183
Sun B, Liu R, Xiao ZD, Zhu X. c-MET protects breast cancer cells from apoptosis induced by sodium butyrate. PLoS One. 7, e30143 (2012)
PubMed link      E-mail link

Reference Number: 1594
McNeil BK, Sorbellini M, Grubb RL 3rd, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, Pinto PA, Bottaro DP Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. J Transl Med. 12, 199 (2014)
PubMed link      E-mail link

Reference Number: 1647
Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL, Cowen EW. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 151, 170-7 (2015)
PubMed link      E-mail link

Reference Number: 1771
Dang Q, Song W, Xu D, Ma Y, Li F, Zeng J, Zhu G, Wang X, Chang LS, He D, Li L. Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog. 54, 831-40 (2015)
PubMed link      E-mail link

Reviews